A Phase 2 interventional study of agenT-797 and Placebo in Pneumonia, sponsored by MiNK Therapeutics. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by MiNK Therapeutics (formerly part of Agenus Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 344 studies in Pneumonia with a site in United States — 41 open to participants now, 51 under way, 6 of them phase 3. Pneumonia · United States.
Among the 344 studies in Pneumonia with a site in United States, this one is the 133rd largest by planned enrollment of the 263 interventional ones that give a count, is one of 13 that started in 2026, is one of 64 in phase 2, reaches primary completion later than 26 of the 48 other live ones, and was the 340th registered.
1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →41 of the 344 studies in Pneumonia with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18+
Quantec Ltd · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 159 Pneumonia studies recruiting now, 85 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
344 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 81 · Phase 3 55 · Phase 4 32
First in 1994; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 128 across 977 interventional studies indexed under Pneumonia.
Median enrollment 91 across the 263 interventional studies, 325 across the 78 observational. Of the 259 that completed or were terminated, 101 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 344 have an industry lead sponsor. The 10 most frequent:
This study is registered under MiNK Therapeutics, one of the names counted as Agenus Inc.. Under that name alone:
MiNK Therapeutics is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Agenus Inc. has 0 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
20 of the studies in Pneumonia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
Add all 20 to your calendar (.ics) → With an account.
Among the 344 studies in Pneumonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
This trial will be conducted in 2 parts (Run-in Phase; Phase 2). The Run-in Phase is designed to characterize the baseline population of the site, where participants will receive open-label agenT-797 plus SOC. After completion of the Run-in Phase, participants will be enrolled and randomized to receive either agenT-797 plus SOC or placebo plus SOC during the double-blinded Phase 2.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive agenT-797 and SOC.
Drug: agenT-797 · Drug: Standard of Care (SOC)
Participants will receive placebo and SOC.
Drug: Placebo · Drug: Standard of Care (SOC)
Intravenous infusion
Intravenous infusion
Antimicrobial therapy and corticosteroids per applicable guidelines.
Number of Deaths (All-cause Mortality)
Time frame: Day 1 through Day 28
Number of Oxygenation Support-free Days
Time frame: Day 1 through Day 28
Time to Resolution of Hypoxemia
Time frame: Day 1 through Day 28
Number of Ventilator-free Days
Time frame: Day 1 through Day 28
Number of Intensive Care Unit-free Days
Time frame: Day 1 through Day 28
Number of Participants Experiencing New Secondary Bacterial, Antimicrobial-resistant, or Fungal Infections
Time frame: Day 1 through Day 28
Number of Antibiotic-free Days
Time frame: Day 1 through Day 28
Time to Hospital Discharge
Time frame: Day 1 through Day 28
Number of Deaths (All-cause Mortality)
Time frame: Day 1 through Day 90
Change From Baseline in Cytokine Profiles
Cytokine profiles analyzed may include interleukin-6, tumor necrosis factor-alpha, interleukin-1-beta, interleukin-1 receptor antagonist, soluble receptor for advanced glycation end product, angiopoietin-1 and -2, and tumor necrosis factor receptor 1.
Time frame: Baseline, Day 3, Day 7, Day 14
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.
Of 64 phase 2 interventional studies under Pneumonia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 13 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Allogeneic Invariant Natural Killer T-cells agenT-797